Press Releases September 18, 2026 04:15 PM

Omega Flex, Inc. Announces Regular Quarterly Dividend for the Third Quarter 2026

Omega Flex Declares $0.34 Quarterly Dividend for Q3 2026, Signaling Confidence in Financial Stability

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
OFLX

Omega Flex, Inc. announced a regular quarterly dividend of $0.34 per share payable on October 14, 2026, reinforcing its commitment to returning value to shareholders. The Board of Directors emphasized that future dividend amounts will be evaluated quarterly based on operational results, financial condition, capital expenditures, and potential acquisitions.

Omega Flex, Inc. Announces Regular Quarterly Dividend for the Third Quarter 2026
OFLX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Declared a $0.34 per share quarterly dividend for Q3 2026 payable October 14, 2026.
  • Dividend decisions will be reviewed quarterly considering financial performance and strategic plans, including capital expenditures and acquisitions.
  • The announcement reflects Omega Flex's stable financial health and ongoing shareholder value strategy.

EXTON, Pa., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Omega Flex, Inc. (the “Company”) today announced that the Board of Directors declared a regular quarterly dividend of $0.34 per share payable on October 14, 2026, to shareholders of record on September 30, 2026. In determining the amount of future regular quarterly dividends, the Board will review the cash needs of the Company, and based on results of operations, financial condition, capital expenditure plans, and consideration of possible acquisitions, as well as such other factors as the Board of Directors may consider relevant, determine on a quarterly basis the amount of a regular quarterly dividend.

INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS – This press release contains forward-looking statements, which are subject to inherent uncertainties which are difficult to predict and may be beyond the ability of Omega Flex to control. Certain statements in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are not historical facts, but rather reflect Omega Flex’s current expectations concerning future results and events. The words “believes,” “expects,” “intends,” “plans,” “anticipates,” “hopes,” “likely,” “will,” and similar expressions identify such forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance, or achievements of Omega Flex (or entities in which Omega Flex has interests) or industry results, to differ materially from future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s view only as of the date of this press release. Omega Flex undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, conditions, or circumstances.

Contact: Dean W. Rivest
(610) 524-7272


Risks

  • Forward-looking statements indicate risks and uncertainties that may affect future results, including operational performance and acquisition outcomes.
  • Dividend amounts are subject to change based on company cash needs and financial condition, potentially impacting investor expectations.
  • Market conditions and unanticipated events could influence the company’s ability to maintain or increase dividend payments.

More from Press Releases

Home BancShares, Inc. Announces Recognition in Forbes Top-Performing Banks and Bank Director RankingBanking Sep 18, 2026 New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients Sep 18, 2026 Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs Sep 18, 2026 Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults Sep 18, 2026 Enact Receives Ratings Upgrade from AM Best Sep 18, 2026